Research

Hormonal

Hepatic overexpression of the enzyme ALOXE3 enhances whole-body insulin sensitivity and reduces weight gain by generating the PPARγ ligand 12-KETE.

This research identifies ALOXE3 as a key enzyme induced by fasting that improves insulin sensitivity by activating PPARγ. While direct supplementation with ALOXE3 is not currently available, the findings suggest that strategies inducing this enzyme, such as fasting or specific glucose transporter blockers (like trehalose), may offer metabolic benefits. Current clinical application is limited as genetic therapy is not yet optimized for polygenic diseases like obesity.

GoodSupportsHIGH confidence
Aloxe3 is, therefore, a potentially novel effector of the hepatocellular fasting response that leverages both PPARγ-mediated and pleiotropic effects to augment hepatic and whole-host metabolism, and it is, thus, a promising target to ameliorate metabolic disease.
Cassandra B. Higgins et al. · JCI Insight · 2018

Why this rating

Strong mechanistic evidence in mouse models (diet-induced and genetic obesity) with clear reversal by inhibitors and genetic deletion, but lacks human clinical trial data.

Source

Hepatocyte ALOXE3 is induced during adaptive fasting and enhances insulin sensitivity by activating hepatic PPARγ

Cassandra B. Higgins et al. · JCI Insight · 2018

DOI 10.1172/jci.insight.120794

mechanism_onlyCited 33×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →